SCHEMBL9894893

SCHEMBL9894893

Cc1nnn(-c2ccc(F)cc2)c1-c1c[nH]cn1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGS2 P35354 5/20 0.40
IDO1 P14902 1/20 0.38
TDO2 P48775 1/20 0.38
LMNA P02545 2/20 0.35
MEN1 O00255 2/20 0.35
KMT2A Q03164 2/20 0.35
NPC1 O15118 1/20 0.35
RAB9A P51151 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
DCTPP1 Q9H773 1/20 0.34
GABRA5 P31644 2/20 0.34
CA1 P00915 4/20 0.33
CA2 P00918 4/20 0.33
CA4 P22748 4/20 0.33
CA9 Q16790 4/20 0.33
CYP17A1 P05093 1/20 0.33
CYP1A2 P05177 1/20 0.33
GABRG2 P18507 1/20 0.33
GABRB3 P28472 1/20 0.33
KCNH2 Q12809 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9894693 0.78 KCNN4 (0.39) MEN1KMT2A
SCHEMBL9894870 0.70 MAPK14 (0.40) KCNH2
SCHEMBL12530467 0.70 PTGS2 (0.60) PTGS2IDO1TDO2LMNAMEN1
SCHEMBL9895924 0.69 RAB9A (0.38) PTGS2IDO1TDO2LMNAMEN1
SCHEMBL9895210 0.67 PTGS2 (0.46) PTGS2LMNANPC1RAB9ASMN1; SMN2
SCHEMBL464496 0.66 MAPK1 (0.40) MEN1KMT2ANPC1RAB9ASMN1; SMN2
SCHEMBL5254408 0.66 BRAF (0.62)
SCHEMBL9895072 0.65 MAPT (0.35) LMNANPC1RAB9ASMN1; SMN2KCNH2
SCHEMBL28807048 0.65 PTGS2 (0.39) PTGS2LMNAMEN1KMT2ASMN1; SMN2
SCHEMBL21834124 0.64 GABRA5 (0.46) PTGS2IDO1TDO2LMNAMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2649064-B1 NOVEL TRIAZOLE COMPOUNDS III HOFFMANN LA ROCHE (CH) 2019-10-02 EP disclosed
EP-2649064-A1 NOVEL TRIAZOLE COMPOUNDS III F. Hoffmann-La Roche AG (CH) 2013-10-16 EP disclosed
US-8466181-B2 1,2,3-triazole-imidazole compounds HOFFMANN-LA ROCHE INC. (US) 2013-06-18 US disclosed
WO-2012076590-A1 NOVEL TRIAZOLE COMPOUNDS III F. HOFFMANN-LA ROCHE AG (CH) 2012-06-14 WO disclosed
US-20120149675-A1 1,2,3-TRIAZOLE-IMIDAZOLECOMPOUNDS HOFFMANN-LA ROCHE INC. 2012-06-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120149675-A1 1,2,3-TRIAZOLE-IMIDAZOLECOMPOUNDS GABRA5, GABRA1, GABRB1 PTGS2 2498/4885IDO1 1029/4885TDO2 2774/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.